Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dale George Nagle has a total of 251 co-authors. Here are the top co-authors by number of shared publications:

  • Yu-Dong Zhou

    Department of Ophthalmology, The First Affiliated Hospital, Zhejiang University School of Medicine, and Nanhu Brain-computer Interface Institute, Hangzhou, 310003, China; School of Brain Science and Brain Medicine, Zhejiang University, No.866 Yuhangtang Road, Xihu District, Hangzhou, 310058, Zhejiang, China

    34 shared publications
  • Yu-Dong Zhou

    Department of Chemistry and Biochemistry, College of Liberal Arts, and

    16 shared publications
  • Mika B. Jekabsons

    13 shared publications
  • Fakhri Mahdi

    12 shared publications
  • Yang Liu

    Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI

    12 shared publications
  • William H. Gerwick

    National Center for Natural Products Research, Department of Pharmacognosy, and Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University, Mississippi 38677-1848, and College of Pharmacy, Oregon State University, Corvallis, Oregon 97331

    11 shared publications

Latest Publications

  • Open Access

    Mechanistic Investigation of Adociaquinone and Xestoquinone Derivatives in Breast Cancer Cells

    by Yu-Dong Zhou, Fakhri Mahdi, Nicholas M. Nagle, Mika B. Jekabsons, Dale G. Nagle

    Xestoquinone derivatives isolated from marine sponges exhibit a range of bioactivities, including the inhibition of HIF signaling, mitochondrial function, and tumor cell proliferation. Mechanistic investigation suggested that 14-hydroxymethylxestoquinone (1) acts as a protonophore. Although adociaquinones A (5) and B (6) each stimulated cellular oxygen consumption, neither affected mitochondrial membrane potential. Cell-based respiration studies revealed that adociaquinones restored sodium azide-stalled oxygen consumption and ascorbate enhanced this response, suggesting ascorbate-supported redox cycling as a possible mechanism by which adociaquinones suppress HIF and tumor cell proliferation. These xestoquinone derivatives activated cellular stress response pathways that inhibit protein translation by phosphorylating key regulatory proteins (i.e., eIF2α, eIF4E, and eEF2). Further, thiol-reducing agents NAC and DTT attenuated the monosubstituted xestoquinone derivatives’ efficacy to inhibit HIF signaling, suggesting a potential mechanism of action that involves sulfhydryl modification.

  • Open Access

    Crizotinib‐based proteolysis targeting chimera suppresses gastric cancer by promoting MET degradation

    by Jin‐Jiao Chen, Jin‐Mei Jin, Wen‐Jie Gu, Zeng Zhao, Hu Yuan, Yu‐Dong Zhou, Dale G. Nagle, Qiu‐Lei Xi, Xue‐Mei Zhang, Qing‐Yan Sun, et al.

    As one of the common malignant cancer types, gastric cancer (GC) is known for late‐stage diagnosis and poor prognosis. Overexpression of the receptor tyrosine kinase MET is associated with poor prognosis among patients with advanced stage GC. However, no MET inhibitor has been used for GC treatment. Like other tyrosine kinase inhibitors that fit the “occupancy‐driven” model, current MET inhibitors are prone to acquired resistance. The emerging proteolysis targeting chimera (PROTAC) strategy could overcome such limitations through direct degradation of the target proteins. In this study, we successfully transformed the MET‐targeted inhibitor crizotinib into a series of PROTACs, recruiting cereblon/cullin 4A E3 ubiquitin ligase to degrade the MET proteins. The optimized lead PROTAC (PRO‐6 E) effectively eliminated MET proteins in vitro and in vivo, inhibiting proliferation and motility of MET‐positive GC cells. In the MKN‐45 xenograft model, PRO‐6 E showed pronounced antitumor efficacy with a well‐tolerated dosage regimen. These results validated PRO‐6 E as the first oral PROTAC for MET‐dependent GC.


  • Targeted Protein Degradation Technology and Nanomedicine: Powerful Allies against Cancer

    by Jia‐Yi Lin, Hai‐Jun Liu, Ye Wu, Jin‐Mei Jin, Yu‐Dong Zhou, Hong Zhang, Dale G. Nagle, Hong‐Zhuan Chen, Wei‐Dong Zhang, Xin Luan

    Targeted protein degradation (TPD) is an emerging therapeutic strategy with the potential of targeting undruggable pathogenic proteins. After the first proof‐of‐concept proteolysis‐targeting chimeric (PROTAC) molecule was reported, the TPD field has entered a new era. In addition to PROTAC, numerous novel TPD strategies have emerged to expand the degradation landscape. However, their physicochemical properties and uncontrolled off‐target side effects have limited their therapeutic efficacy, raising concerns regarding TPD delivery system. The combination of TPD and nanotechnology offers great promise in improving safety and therapeutic efficacy. This review provides an overview of novel TPD technologies, discusses their clinical applications, and highlights the trends and perspectives in TPD nanomedicine.


  • Open Access

    Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer

    by Jinmei Jin, Yaping Wu, Zeng Zhao, Ye Wu, Yu-Dong Zhou, Sanhong Liu, Qingyan Sun, Guizhu Yang, Jiayi Lin, Dale G. Nagle, et al.

    The aberrant activation of STAT3 is associated with the etiology and progression in a variety of malignant epithelial-derived tumors, including head and neck squamous cell carcinoma (HNSCC) and colorectal cancer (CRC). Due to the lack of an enzymatic catalytic site or a ligand-binding pocket, there are no small-molecule inhibitors directly targeting STAT3 that have been approved for clinical translation. Emerging proteolysis targeting chimeric (PROTAC) technology–based approach represents a potential strategy to overcome the limitations of conventional inhibitors and inhibit activation of STAT3 and downstream genes. In this study, the heterobifunctional small-molecule–based PROTACs are successfully prepared from toosendanin (TSN), with 1 portion binding to STAT3 and the other portion binding to an E3 ubiquitin ligase. The optimized lead PROTAC (TSM-1) exhibits superior selectivity, potency, and robust antitumor effects in STAT3-dependent HNSCC and CRC — especially in clinically relevant patient-derived xenografts (PDX) and patient-derived organoids (PDO). The following mechanistic investigation identifies the reduced expression of critical downstream STAT3 effectors, through which TSM-1 promotes cell cycle arrest and apoptosis in tumor cells. These findings provide the first demonstration to our knowledge of a successful PROTAC-targeting strategy in STAT3-dependent epithelial cancer.


  • CD47: Beyond an immune checkpoint in cancer treatment

    by Hui-Ting Bian, Yi-Wen Shen, Yu-Dong Zhou, Dale G. Nagle, Ying-Yun Guan, Wei-Dong Zhang, Xin Luan


  • Open Access

    Polymer chimera of stapled oncolytic peptide coupled with anti-PD-L1 peptide boosts immunotherapy of colorectal cancer

    by Lu Lu, He Zhang, Yudong Zhou, Jiayi Lin, Weidong Gao, Ting Yang, Jinmei Jin, Lijun Zhang, Dale G. Nagle, Weidong Zhang, et al.

    Rationale: Scarce tumor mutation burden and neoantigens create tremendous obstacles for an effective immunotherapy of colorectal cancer (CRC). Oncolytic peptides rise as a promising therapeutic approach that boosts tumor-specific immune responses by inducing antigenic substances. However, the clinical application of oncolytic peptides has been hindered because of structural instability, proteolytic degradation, and undesired toxicity when administered systemically.


  • Open Access

    The multifaceted involvement of exosomes in tumor progression: Induction and inhibition

    by Wen‐Jie Gu, Yi‐Wen Shen, Li‐Jun Zhang, Hong Zhang, Dale G. Nagle, Xin Luan, San‐Hong Liu

    As key performers in intercellular communication, exosomes released by tumor cells play an important role in cancer development, including angiogenesis, cancer-associated fibroblasts activation, epithelial-mesenchymal transformation (EMT), immune escape, and pre-metastatic niche formation. Meanwhile, other cells in tumor microenvironment (TME) can secrete exosomes and facilitate tumor progression. Elucidating mechanisms regarding these processes may offer perspectives for exosome-based antitumor strategies. In this review, we mainly introduce the versatile roles of tumor or stromal cell derived exosomes in cancer development, with a particular focus on the biological capabilities and functionalities of their diverse contents, such as miRNAs, lncRNAs, and circRNAs. The potential clinical application of exosomes as biomarkers in cancer diagnosis and prognosis is also discussed. Finally, the current antitumor strategies based on exosomes in immunotherapy and targeted delivery for chemotherapeutic or biological agents are summarized.


  • Open Access

    Application of omics- and multi-omics-based techniques for natural product target discovery

    by Hong-Wei Zhang, Chao Lv, Li-Jun Zhang, Xin Guo, Yi-Wen Shen, Dale G. Nagle, Yu-Dong Zhou, San-Hong Liu, Wei-Dong Zhang, Xin Luan


  • Stapled Wasp Venom-Derived Oncolytic Peptides with Side Chains Induce Rapid Membrane Lysis and Prolonged Immune Responses in Melanoma

    by Ye Wu, Dong Lu, Yixin Jiang, Jinmei Jin, Sanhong Liu, Lili Chen, Hong Zhang, Yudong Zhou, Hongzhuan Chen, Dale G. Nagle, et al.

    Peptide stapling chemistry represents an attractive strategy to promote the clinical translation of protein epitope mimetics, but its use has not been applied to natural cytotoxic peptides (NCPs) to produce new oncolytic peptides. Based on a wasp venom peptide, a series of stapled anoplin peptides (StAnos) were prepared. The optimized stapled Ano-3/3s were shown to be protease-resistant and exerted superior tumor cell-selective cytotoxicity by rapid membrane disruption. In addition, Ano-3/3s induced tumor ablation in mice through the direct oncolytic effect and subsequent stimulation of immunogenic cell death. This synergistic oncolytic-immunotherapy effect is more remarkable on melanoma than on triple-negative breast cancer in vivo. The efficacies exerted by Ano-3/3s on melanoma were further characterized by CD8+ T cell infiltration, and the addition of anti-CD8 antibodies diminished the long-term antitumor effects. In summary, these results support stapled peptide chemistry as an advantageous method to enhance the NCP potency for oncolytic therapy.


  • Open Access

    Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins

    by Jiayi Lin, Jinmei Jin, Yiwen Shen, Lijun Zhang, Gang Gong, Huiting Bian, Hongzhuan Chen, Dale G. Nagle, Ye Wu, Weidong Zhang, et al.

    Classic small molecule inhibitors that directly target pathogenic proteins typically rely on the accessible binding sites to achieve prolonged occupancy and influence protein functions. The emerging targeted protein degradation (TPD) strategies exemplified by PROteolysis TArgeting Chimeras (PROTACs) are revolutionizing conventional drug discovery modality to target proteins of interest (POIs) that were categorized as “undruggable” before, however, these strategies are limited within intracellular POIs. The novel new degrader technologies such as LYsosome-TArgeting Chimaeras (LYTACs) and Antibody-based PROTACs (AbTACs) have been successfully developed to expand the scope of TPD to extracellular and membrane proteins, fulfilling huge unmet medical needs. Here, we systematically review the currently viable protein degradation strategies, emphasize that LYTACs and AbTACs turn a new avenue for the development of TPD, and highlight the potential challenges and directions in this vibrant field.